A new cancer pain treatment drug, Abstral, will be released
in France this month by the pharmaceutical company ProStrakan Group. ProStrakan
Group has completed the reimbursement pricing process with French authorities
for the product launch.
The cancer drug Abstral is a new formulation of fentanyl. It can be used by
cancer patients who are already using opioid analgesics for their pain
management. The drug will help manage breakthrough pain episodes.
Abstral was recommended and approved in the European Union by
the Committee for Medicinal Products for Human Use of the European Medicines
Agency in June 2008. Regulators in France authorized the marketing for Abstral
on February 23, 2009. Abstral has been available in Germany and the UK since
January 2009.
Source : Mesothelioma News
